Last reviewed · How we verify

Maintenance of Healing Gastric Ulcer — Treatment Landscape & Competitive Intelligence

Maintenance of Healing Gastric Ulcer (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Maintenance of Healing Gastric Ulcer, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Zantac ranitidine GSK (originally Glaxo) H2 receptor antagonist Multidrug and toxin extrusion protein 1, Acetylcholinesterase, Histamine H2 receptor 1983-06-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. GSK (originally Glaxo) · 1 drug in Maintenance of Healing Gastric Ulcer

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Maintenance of Healing Gastric Ulcer:

Cite this brief

Drug Landscape (2026). Maintenance of Healing Gastric Ulcer — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/maintenance-of-healing-gastric-ulcer. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing